Chcete zobrazit informace, které jsou určeny výhradně odborníkům (podle § 2a zákona č. 40/1995 Sb., o regulaci reklamy, v platném znění), tedy osobám oprávněným léčivé přípravky předepisovat, nebo vydávat.
  1. Kliknutím na tlačítko "ANO" výslovně prohlašuji a potvrzuji, že jsem odborníkem, tedy osobou oprávněnou léčivé přípravy vydávat či předepisovat. V případě, že nepatříte mezi osoby oprávněné léčivé přípravky předepisovat, nebo vydávat, opusťte prosím tyto stránky stisknutím tlačítka NE.
  2. Kliknutím na tlačítko "ANO" výslovně prohlašuji a potvrzuji, že je mi známa definice odborníka. V případě, že nikoliv nebo v případě, že nepatříte mezi osoby oprávněné léčivé přípravky předepisovat, nebo vydávat, opusťte prosím tyto stránky stisknutím tlačítka NE.
  3. Pro případ, že nejsem odborníkem, pak jsem seznámen s riziky, kterým se vystavuji v důsledku možného chybného vyhodnocení informací, které jsou určeny odborníkům, přičemž tato rizika zcela akceptuji.
Přejete-li si pokračovat a tím potvrdit, že jste tímto odborníkem, stiskněte ANO.
AnoNe
Hlavní stránka        Úvod pro odborníky        O firmě        Kontakty        Pomáháme druhým        Poradna       Semináře
Literatura

Literatura

Časopisy s Impact faktorem

A - B - C - D - E - G - H - Ch - J - K - L - M - N - O - P - R - S - T - W -Z


Abstracts of The 7th Interscience World Conference on Inflammation, Antirheumatics, Analgetics, Immunomodulators. Geneva 1997. International Journal of Tissue Reactions
XIX (1/2): 86-99, 1997.
Impact factor: 0,444


Beuth J., Ost B., Pakdaman A., Rethfeldt E., Bock P.R., Hanisch J., Schneider B.: Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients - results of an epidemiological multicentre retrolective cohort study. Cancer Chemotherapy and Pharmacology 47: S45-S54, 2001.
Impact factor: 1,928 Onk-129


Calnan, J.: The prevention of post-operative oedema. Controlled clinical trial of lyophilised chymotrypsin in plastic surgery. Brit. Med. J. 261-263, 1960.


Dale P.S., Tamhankar Ch.P., George D., Daftary G.V.: Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects. Cancer Chemotherapy and Pharmacology 47: S29-S34, 2001. Onk-3

Derveniece A., Hartmane I., Mikazans I., Rozniece K., Ivdra I. : Aciclovir and Wobenzym combination in treatment of genital herpes.International Journal of STD and AIDS 13 (suppl. 1); 42 (2002).
Impact factor: 1,394

Desser L, Herbacek l., Závadová E., Mohr T.: Conversion of α2-Macroglobulin (α2-M) to the fast-form by Wobenzym® interrupts the autocrine loop of TGF-β production in melanoma cells. The European Journal of Cancer 35 (4): No. 1526, 375, 1999.
Impact factor: 3,562 Onk-79

Desser L, Holomanova D., Závadová E., Pavelka K., Mohr T., Herbacek I.: Oral therapy with proteolytic enzymes decreases excessive TGF-β levels in human blood. Cancer Chemotherapy and Pharmacology 47: S10-S15, 2001. Imun-25

Desser L., Rehberger A., Kokron E., Paukovits W.: Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparations. Oncology 50: 403-407, 1993.
Impact factor: 2,141 Imuno-26

Desser L., Sakalová A., Závadová E., Holomanova D., Mohr T.: Concentrations of soluble tumor necrosis factor receptors, β2-microglobulin, IL-6 and TNF in serum of multiple myeloma patients after chemotherapy and after combined enzyme + chemotherapy. International Journal of Immunotherapy XIII (3/4): 121-130, 1997.
Impact factor: 0,172 Exp-22

Desser L., Zavadova E., Herbacek I.: Oral enzymes as additive cancer therapy. Int.J.Immunotherapy XVII(2/3/4) 153-161 (2001).
Impact factor: 0,242

Dosenkov V.E., Zaharova V.P., Byts Y.V. : Systemic enzyme therapy in experimental atherosclerosis. Int.J.Immunotherapy XVII(2/3/4) 51-58 (2001).
Impact factor: 0,242

Dušková M., Wald M.: Orally administered proteases in aesthetic surgery. Aesthetic Plastic Surgery 23 (1): 41-4, 1999.
Impact factor: 0,366 CH-25


Emancipator S.N., Chintalacharuvu S.R., Urankar Nagy N., Petersilge C., Stauder G.: Effects of oral enzymes in collagen II induced arthritis in mice. International Journal of Immunotherapy XIII (3/4): 67-74, 1997.
Impact factor: 0,172 Exp-27

Emancipator S.N., Chintalacharuvu S.R., Urankar Nagy N., Stauder G.: Oral enzymes in different animal models of glomerulonephritis. International Journal of Immunotherapy XIII (3/4): 97-103, 1997.
Impact factor: 0,172 Exp-25

Ernst E.: Oral therapy with proteolytic enzymes: Effects on hemorheological parameters.
Perfusion 12: 440-441, 1994.
Impact factor: 0,534


Gaciong Z., Paczek L, Bojakowski K., Socha K., Wisniewski M., Heidland A.: Beneficial effect of proteases on allograft arteriosclerosis in a rat aortic model. Nephrology Dialysis Transplantation 11 (6): 987-989, 1996.
Impact factor: 1,628 Exp-29

Garbin F., Harrach T., Eckert K., Maurer M.: Bromelain proteinase F9 augments human lymphocyte-mediated growth inhibition of various tumor cells in vitro. International Journal of Oncology 5: 197-203, 1994.
Impact factor: 1,181 Exp-31

Gebauer F., Micheel B., Stauder G., Ransberger K., Kunze R.: Proteolytic enzymes modulate the adhesion molecule CD44 on malignant cells in vitro. International Journal of Immunotherapy XIII (3/4): 111-119, 1997.
Impact factor: 0,172 Exp-32

Gesualdo L, Ricanati S., Medhat 0. Hassan, Emancipator S.N., Lamn M.E.: Enzymolysis of glomerular immune deposits in vivo with dextranase/protease ameliorates proteinuria, hematuria, and mesangial proliferation in murine experimental IgA nephropathy. Journal of Clinical Investigation 86: 715-722, 1990.
Impact factor: 9,667 Far_mech-14

Guangsheng X., Schinzel R., Simm A., Sebekova K., Heidland A.: Advanced glycation end products impair protein turnover in LLC-PK1: Amelioration by trypsin. Kidney International, Vol. 59, Suppl. 78 (2001), pp. S-53 - S-57.
Impact factor: 5,016

Gujral M.S., Patnaik P.M., Kaul R., Daftary G.V., Parikh H.K., Tamhankar C.P., Schiess W.: Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. The European Journal of Cancer 35 (4): No. 543, 168, 1999.
Impact factor: 3,562 Onk-8

Gujral M.S., Patnaik P.M., Kaul R., Parikh H.K., Conradt Ch., Tamhankar Ch.P., Daftary G.V.:
Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemotherapy and Pharmacology 47: S23-S28, 2001.
Impact factor: 1,928 Onk-8


Hall S.W., LaMarre J., Marshall L.B., Hayes M.A., Gonias S.L: Binding of transforming growth factor-beta 1 to methylamine-modified alpha 2-macroglobulin and to binary and ternary alpha 2-macroglobulin-proteinase complexes. Biochem J (2): 569-575, 1992.

Hale L.P., Haynes B.F.: Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CDS, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. Journal of Immunology 149 (12): 3809-3816, 1992.
Impact factor: 6,937 Exp-35

Harrach T., Gebauer F., Eckert K., Kunze R., Maurer H.: Bromelain proteinases modulate CD44 expression on human Molt 4/8 leukemia and SK- Mel 28 melanoma cells in vitro. International Journal of Oncology 5: 485-488, 1994.
Impact factor: 1,181 Exp-36

Heidland A., Sebekova K., Paczek L., Teschner M., Dammrich J., Gaciong Z.: Renal fibrosis: Role of impaired proteolysis and potential therapeutic strategies. Kidney International 52 (62): 32-35, 1997.
Impact factor: 4,071 Exp-38

Heinz H.P., Loos M.: Activation of the first component of complement, Cl: comparison of the effect of 16 different enzymes on serum Cl. Immunobiology 165: 175-185, 1983.
Impact factor: 1,378

Heumann D., Vischer T.L: Immunomodulation by alfa2-macroglobulin-proteinase complexes: the effect on the human T lymphocyte response. European Journal of Immunology 18: 755-760, 1988.
Impact factor: 5,256 Exp-39


Chintalacharuvu S.R., Uranakr-Nagy N., Petersilge CH.A., Abdul-Karim F.W., Emancipator S.N.: Treatment of collagen induced arthritis by proteolytic enzymes: immunomodulatory and disease modifyng effects. The Journal of Rheumatology 28 (9); 2049-2059 (2001).
Impact factor: 2,987


James K.: Interactions between cytokines and alfa2-macroglobulin. Immunology Today 11: 163-166, 1990.
Impact factor: 16,465 Far_mech-20

Jutila et al., Low-dose chymotrypsin treatment inhibits neutrophil migration into sites of inflammation in vivo: effects on Mac-1 and MEL-14 adhesion protein expression and function.
Cellular Immunology. 132, pp. 201-214 (1991). Exp-40


Kafková H., Kojanová M.: Lymfedém. Posgraduální medicína 5 (6); 626-633 (2003).
Impact factor: 1,394

Khryanin A.A., Lykova S.G.: Oral enzymes improve the efficacy of Chlamydia trachomatis infection treatment.International Journal of STD and AIDS 13 (suppl. 1); 41,2002.
Impact factor: 1,394

Kleef R., Delohery T.M., Bovbjerg D.H.: Selective modulation of cell adhesion molecules on lymphocytes by bromelain protease 5. Pathobiology 64: 339-346, 1996.
Impact factor: 0,652 Exp-43

Klein G., Kullich W.: Kurzzeitbehandlung mit oralen Enzymen bei schmerzhafter Osteoarthrose des Knies. Clin Drug Invest 19 (1): 15-23, 2000.
Impact factor: 0,914 R-5

Kokron E., Rehberger A., Desser L.: Influence of cytokines and proteolytic enzymes on the expression of vitronectin-receptor (VNR) in human melanoma cells. Journal of Cancer Research and Clinical Oncology 118: 117, 1992.

Koshkin V.M., Kirienko A.I.: Systemic enzyme therapy in the treatment of acute thrombosis of superficial veins in the lower extremites and postthrombophlebitic disease. Int.J.Immunotherapy XVII(2/3/4) 121-124,2001.
Impact factor: 0,242

Kovalenko V., Shuba N.M., Golovatskiy I.V., Bortkevich O.P.: Estimation of efficacy of basic therapy of rheumatoid arthritis on the basis of systemic enzyme therapy:Results of five-year monitoring. Int.J:Immunotherapy XVII(2/3/4)129-133, 2001.
Impact factor: 0,242

Kovalenko V., Sledzevskaya I.K., Ryabokon E.N., Gavrilenko T.I.: New aproaches to modern cardiology based on systematic enzyme therapy. Int.J.Immunotherapy XVII(2/3/4) 101-111, 2001.
Impact factor: 0,242


Lackovic V., Rovensky J., Horvathova M., Malis F.: Interferon production in whole blood cultures from volunteers and rheumatoid arthritis patients after medication with oral enzymes. International Journal of Immunotherapy XIII (3/4): 159-165, 1997.
Impact factor: 0,172 R-36

Lauer D., Müller R., Cott Ch., Otto A., Naumann M., Birkenmeier G.: Modulation of growth factor binding properties of α2-macroglobulin by enzyme therapy. Cancer Chemotherapy and Pharmacology 47: S4-S9, 2001.
Impact factor: 1,928 Far_mech-30

Lauer D., Reichenbach A., Birkenmeier G.: α2-makroglobulin-mediated degradation of amyloid βl-42: mechanism to enhace amyloid β catabolism. Experimental Neurology 167: 385-392, 2001.
Impact factor: 3,641 Far_mech-31

Lehmann P.V.: Immunomodulation by proteolytic enzymes. Nephrology Dialysis Transplantation 11 (6): 953-955, 1996.
Impact factor: 1,682


Madar J., Ulcova-Gallova Z., Sula K., Kucera E., Peknicova J., Chaloupkova A., Nouza K., Kinsky R.: Immunopathological Mechanisms in recurrent miscarriage and preeclampsoia. American Journal of Reproductive Immunology 46 (1); 96 (2001).
Impact factor: 1,413

Malook S.G., Pravas P.M., Rashmi K., Hemen K.P., Conradt Ch., Tamhankar Ch.P., Daftary G.V.: Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemother Pharmacol 47.; 2001.
Impact factor: 1,928.

Manhart N., Akomeah R., Bergeister H., Spittler A., Ploner M., Roth E.: Administration of proteolytic enzymes bromelain and trypsin diminish the number of CD4+ cells and the interferon-γ response in Peyer's patches and spleen in endotoxemic balb/c mice.Cellular Immunology 215; 113-119 (2002).
Impact factor: 1,988

Maurer H.R.: Bromelain: biochemistry, pharmacology and medical use. CMLS, Cell. Mol. Life Sci. 58; 1234-1245 (2001).
Impact factor: 5,259

May C., Smola M., Ruda C., Scharnagl E.: Randomized open controlled clinical study on the efficacy and tolerance of an oral enzyme preparation in lymphadenectomy patients. Int.J.Immunotherapy XVII(2/3/4) 149-152 (2001).
Impact factor: 0,242

Mazurov V.I., Lila A.M.: Optimization of reactive arthritis treatment using systemic enzyme therapy. Int.J.Immunotherapy XVII(2/3/4) 125-128 (2001).
Impact factor: 0,242

Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V., Makulova T.G.: The efficacy of systemic enzyme therapy in the treatment of rheumatoid arthritis. International Journal of Immunotherapy XIII (3/4): 85-91, 1997.
Impact factor: 0,172 R-7

Menssen H.D., Sakalová A., Fontana A., Herman Z., Boewer Z., Facon T., Lichinister M.R., Singer C.R.J., Euller-Ziegler L., Wetterwald M., Fiere D., Hrubisko M., Thiel E., Delmas P.D.: Effects of long term intravenous ibandronate therapy on skeletal-related events, survial, and bone resorption markers in patients with advanced multiple myeloma.Journal of Clinical Oncology 20 (9); 2353-2359 (2002).
Impact factor: 9,868

Mohr T., Závadová E., Hauptmann E., Maca S., Neumann M., Salzer H., Micksche M.:
Modulation of human tumor associated macrophages from malignant effusions with cytokines and proteolytic enzymes. The European Journal of Cancer 35 (4): No. 1448, 357, 1999.
Impact factor: 3,562 Far_mech-35

Moore, F.T.: A report on seventy-five patients treated with Chymar (lyophilised chymotrypsin). Brit. J. plast. Surg. : 335-339, 1962.

Mudrák J., Bobák L., Šebová I.: Adjuvant Therapy with Hydrolytic Enzymes in Recurrent Laryngeal Papillomatosis. Acta Oto-Laryngologica (Stockh) 527: 128-130, 1997.
Impact factor: 0,603 ORL-16

Munzig E., Eckert K., Harrach T., Graf H., Maurer H.R.: Bromelain protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells. FEBS Letters 351: 215-218, 1994.
Impact factor: 3,504


Nakazawa M., Emancipator S.N., Lamn M.E.: Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis. Journal of Experimental Medicine 164: 1973-1987, 1986.
Impact factor: 14,384 Nefro-19

Nouza K., Madar J.: Immunomodulation in the treatment of reproduction disturbances. American Journal of Reproductive Immunology 46 (1); 106 (2001).
Impact factor: 1,413 Gyn-20

Nortier J. et al., Enzymatic degradation of tumor necrosis factor by activated human neutrophils: role of elastase. Life Sci., 49, 25, 1991


Österreicher J., Škopek J., Navrátil L., Knížek J., Šebková V., Máčela A.: Enteral administration of proteinase mixture inhibits development of postradiation pneumonitis and lung fibrosis in rats. Int. J. Immunotherapy XVII (2/3/4): 51-58, 2001.
Impact factor: 0,242


Popiela T., Kulig J., Hanisch J., Bock P.R.: Influence of a complementary treatment with oral enzymes on patients with colorectal cancers - an epidemiological retrolective cohort study. Cancer Chemotherapy and Pharmacology 47: S55-S63, 2001.
Impact factor: 1,928 Onk-26


Rovenská E., Švík K., Stančíková M., Rovenský J.: Inhibitory effect of enzyme therapy and combination therapy with cyclosporin A on collagen-induced arthritis. The Journal of Rheumatology 28 (supplement 63); 91 (2001).
Impact factor: 2,987


Sakalová A., Bock P.R., Dědík L., Hanisch J., Schiess W., Gážová S., Chabroňová l., Holomanova D., Mistrík M, Hrubiško M.: Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemotherapy and Pharmacology 47: S38-S44, 2001.
Impact factor: 1,928 Onk-28

Sakalova A., Desser L., Závadová E., Holomanova D., Mohr T.: Enzyme therapy improved remission time, soluble TNF- receptors and β2-microglobulin concentration in chemotherapy treated multiple myeloma patients. British Journal of Haematology 102 (1): 353, 1998.
Impact factor: 3,370

Saradeth T., Quittan M., Ghanewm A.H., Ernst E.: Improvement in blood fluidity characteristics via Phlogenzym - An in vitro pilot study. Perfusion 6: 196-198, 1995.
Impact factor: 0,534 Angio-50

Schedler M., Lind A., Schätzle W., Stauder G.: Adjuvant therapy with hydrolytic enzymes in oncology - a hopeful effort to avoid bleomycinum induced pneumotoxicity? Journal of Cancer Research and Clinical Oncology 116: 697, 1990.

Šebeková K., Dämmrich J., Fierlbeck W., Krivošíková Z., Paczek L, Heidland A.: Systemic treatment with proteolytic enzymes in rat models of nonimmune mediated renal diseases. International Journal of Immunotherapy XIII (3/4): 79-83, 1997.
Impact factor: 0,172 Exp-59

Šebeková K., Dämrich J., Fierlbeck W., Krivosiková Z., Paczek L. Heidland A.: Effect of chronic therapy with proteolytic enzymes on hypertension induced renal injury in the rat model of goldblatt hypertension. The American Journal of Nephrology 18; 570-576 (1998).
Impact factor: 1,476 Exp-58

Šebeková K., Dämmrich J., Krivosiková Z., Heidland A.: The effect of oral protease administration in the rat remnant kidney model. Res Exp Med 199: 177-188, 1999.
Impact factor: 1,194 Exp-60

Shaikov A.V., Movsisyan G.R., Stolyarova A.V.: Wobenzym in the treatment of patients with juvenile chronic arthritis. International Journal of Immunotherapy XIII (3/4): 93-96, 1997.
Impact factor: 0,172

Singer F., Singer C., Oberleitner H.: Phlogenzym versus diclofenac in the treatment of activited osteoarthritis of the knee. A double-blind prospective randomized study. Int.J.Immunotherapy XVII(2/3/4) 135-141, 2001.
Impact factor: 0,242

Skutelis A., Pule E., Purvins I., Baltkajs J., Skromanis M., Zeibarts M., Desser L., Österreicher J, Ansbergs J.: Phlogenzym may prevent metabolic injures to myocardium. Results of a laboratory experiment with rats. Int.J.Immunotherapy XVII(2/3/4) 59-64, 2001.
Impact factor: 0,242

Solyanik G.I., Todor I.N., Yurchenko O.V., Ponomareva O.V., Banakhevych N.V., Terzov A.I., Chekhun V.F.: Reduction of cisplatin-induced nephrotoxicity by proteolytic enzymes in tumor-bearing rats. Int.J.Immunotherapy XVII(2/3/4) 75-81, 2001.
Impact factor: 0,242

Stauder G., Donnerstag B., Baumhackl U., Buschmans E.: Use of oral enzymes in multiple sclerosis: Phenotyping of peripheral blood lymphocytes from MS patients under long-term treatment with orally administered hydrolytic enzymes. International Journal of Immunotherapy XIII (3/4): 135-137, 1997.
Impact factor: 0,172 Neur-12

Stauder G., Kabil S.: Oral enzyme therapy in hepatitis C patients. International Journal of Immunotherapy XIII (3/4): 153-158, 1997.
Impact factor: 0,172

Suchich G.T., Loginova N.S., Faizullin L.Z., Zdanov A.V., Malinina E.V., Bozedomov V. A.:
The use of Wobenzym® to facilitate interferon synthesis in the treatment of chronic urogenital chlamydiosis. International Journal of Immunotherapy XIII (3/4): 131-133, 1997.
Impact factor: 0,172 G-22

Sy M.S., Liu D., Kogerman P., Culp L.A.: Potential of targeting cell surface CD44 proteins with proteinases in preventing tumor growth and metastasis. International Journal of Immunotherapy XIII (3/4): 105-109, 1997.
Impact factor: 0,172 Exp-70


Trevani A.S., Andonegui G., Giordano M., Nociari M., Fontán P, Dran G., Geffner J. R.:
Neutrophil Apoptosis Induced by Proteolytic Enzymes. Laboratory Investigation 74 (3): 711-721,1996.
Impact factor: 4,653 Obec-14


Wald M., Olejár T., Poučková P., Zadinova M.: Proteinases reduce metastatic dissemination and increase survival time in C57BI6 mice with the Lewis lung carcinoma. Life Sciences 63 (17): 237-243, 1998.
Impact factor: 2,275 Exp-76

Wald M., Olejár T., Poučková P., Zadinova M.: The influence of proteinases on in vivoblastic transformation in rat species SD/lpcv with spontaneous lymphoblastic leukemia.
British Journal of Haematology 102 (1): 294, 1998.
Impact factor: 3,370 Exp-77

Wald M., Olejar T., Šebková V., Zadinova M., Boubelík M., Poučková P.: Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57BI6 mice with syngeneic melanoma B16. Cancer Chemotherapy and Pharmacology 47: S16-S22, 2001.
Impact factor: 1,928 Onk-120

Wald M., Poučková P., Hloušková D., Altnerová M., Olejár T.: The influence of trypsin, chymotrypsin and papain on the growth of human pancreatic adenocarcinoma transplanted to nu/nu mice. The European Journal of Cancer 35 (4): No. 543, 148, 1999.
Impact factor: 3,562 Exp-79

Wald M., Závadová E., Poučková P., Zadinova M., Boubelík M.: Polyenzyme preparation Wobe-Mugos® inhibits growth of solid tumors and development of experimental metastases in mice. Life Sciences 62 (3): 43-48, 1998.
Impact factor: 2,275 Exp-82

Wiest-Ladenburger U., Richter W., Moeller P., Boehm B.O.: Protease treatment delays diabetes onset in diabetes-prone nonobese diabetic (NOD) mice. International Journal of Immunotherapy XIII (3/4): 75-78, 1997.
Impact factor: 0,172 Exp-85

Wittenborg, Bock P.R., Hanisch J., Sailer R., Schneider B.: Comparative epidemiological study in patients with rheumatic diseases illustrated in an example of a treatment with non-steroidal anti-inflammatory drugs versus an oral enzyme combination. Drug Research 50 (8): 728-738, 2000.
Impact factor: 0,914 R-20

Wood G.R., Ziska T., Morgenstern E., Stauder G.: Sequential effects of an oral enzyme combination with rutosid in different in vitro and in vivo models of inflammation. International Journal of Immunotherapy XIII (3/4): 139-145, 1997.
Impact factor: 0,172 Exp-87


Zänker K.S.: The use of systemic enzyme therapy in oncology. Cancer Chemotherapy and Pharmacology 47: S1-S3, 2001.
Impact factor: 1,928

Závadová E., Desser L, Mohr T.: Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation. Cancer Biotherapy 10 (2): 147-152, 1995.
Impact factor: 0,781 Exp-92

Závadová E., Desser L: Proteolytic enzymes stimulate the cytotoxic activity of human granulocytes in vitro and in vivo. International Journal of Immunotherapy XIII (3/4): 147-151, 1997.
Impact factor: 0,172

Závadová E., Loercher A., Verstovsek S., Verschraegen C., Micksche M., Freedman R.S.: The role of macrophages in antitumor defense of patients with ovarian cancer. Hematology/Oncology Clinics of North America 1 (13): 135-144, 1999.
Impact factor: 2,096

Závadová E., Savary C., Freedman R.S.: Maturation of dendritic cells (D.C.) from ovarian cancer patients. Clinical Cancer Res. 5 (152), 1999.
Impact factor: 5,991

Zavadova E., Savary Ch.A., Templin S., Verschraegen C.F., Freedmann R.S.: Maturation of dendritic cells from ovarian cancer patients. Cancer Chemother Pharmacol (2001) 48: 289-296.
Impact factor: 1,928 Exp-92

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Lék pro vnitřní užití. Čtěte pečlivě příbalovou informaci.
Inzertní stránky společnosti MUCOS Pharma CZ, s.r.o. - tel: (+420)-267 750 003